Catumaxomab (Paperback)

Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Catumaxomab (trade name Removab) is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in patients with metastasizing cancer. It binds to antigens CD3 and EpCAM. It is in clinical trials in the United States currently and is used in Europe. It was developed by Fresenius Biotech and Trion Pharma (Germany). Catumaxomab was developed by Trion Pharma, based on preliminary work by the Helmholtz Zentrum M nchen. Fresenius Biotech conducted clinical trials and filed the drug for approval with the European Medicines Agency (EMA). It was approved in Europe on 20 April 2009.